GYNE-SULF Drug Patent Profile

Which patents cover Gyne-sulf, and when can generic versions of Gyne-sulf launch?

Gyne-sulf is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in GYNE-SULF is triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole). There are five drug master file entries for this compound. Additional details are available on the triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole) profile page.

Summary for GYNE-SULF

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	3
DailyMed Link:	GYNE-SULF at DailyMed

US Patents and Regulatory Information for GYNE-SULF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	GYNE-SULF	triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole)	CREAM;VAGINAL	088607-001	Jun 9, 1986		DISCN	No	No

Last updated: July 2, 2026

GYNE-SULF Market Dynamics and Financial Trajectory (US & International): Sales Drivers, Pricing, Competition, and IP Overhang

GYNE-SULF market performance is driven by (1) channel mix and reimbursement, (2) defensibility of the active ingredients and formulation, (3) generic and private-label substitution risk, and (4) regional regulatory status that determines when competitors can launch. Financial trajectory hinges on whether the product faces imminent patent or exclusivity expiry, and whether rivals have cleared FDA and/or local equivalent requirements in each geography.

What is GYNE-SULF and what commercial category does it sit in?

Featured snippet: GYNE-SULF is commercially evaluated like an oral anti-infective/anti-inflammatory small-molecule drug where substitution and reimbursement rules typically govern penetration, and where patent-formulation or method-of-use patents determine long-term revenue protection.

Drug identity and commercial positioning

• Active ingredient and strength: Not provided.
• Dosage form: Not provided.
• Indication(s): Not provided.
• Key markets: Not provided.
• Regulatory pathway (FDA/EMA): Not provided.

Pricing and reimbursement model

• For anti-infective and OTC-adjacent products, net pricing usually tracks:
  • payer formulary placement,
  • wholesale acquisition cost adjustments,
  • channel discounts,
  • and competitive launch timing.

What market dynamics shape GYNE-SULF demand?

Featured snippet: Demand typically expands through prescriber familiarity and payer coverage, then compresses as generics enter or as therapeutic alternatives gain share.

Primary demand drivers

1. Clinical switching behavior

   • Providers often standardize to a single brand when coverage is stable.
   • Switching increases after competitor pricing gaps widen or stocking restrictions ease.

2. Reimbursement and formulary access

   • Formulary tier placement affects volume more than list price.
   • Step edits/prior authorization can slow uptake of substitutes but rarely prevent it once a competitor secures favorable coverage.

3. Channel and inventory behavior

   • For small-molecule drugs, distributor ordering cycles and safety-stock policies influence short-term sales “lumpiness.”
   • Launch and discontinuation signals typically show up first in pharmacy wholesaler movement, then retail claims.

Primary supply and substitution dynamics

1. Generic entry risk

   • If there is an Orange Book patent barrier (process/formulation), generics may launch “at risk” later or not at all.
   • If the patent estate is thin, pricing pressure hits quickly after first approved ANDA.

2. Parallel trade and cross-border arbitrage

   • In markets with differential pricing and reimbursement controls, cross-border supply can distort local pricing and volumes.

How does pricing erosion typically play out for branded products like GYNE-SULF?

Featured snippet: Net sales generally follow a stair-step pattern: stable pricing pre-entry, sharp compression at first generic, then slower declines as remaining brand share normalizes.

Price and discount mechanics

• Brand manufacturers typically respond with:
  • contracting and rebate escalation,
  • pack-size changes,
  • and targeted payer negotiations.
• Post-generic, price becomes a function of:
  • competitive list-price benchmarks,
  • rebate convergence,
  • and payer preference for AB-rated alternatives.

What matters most for net sales

• Launch timing of first generic/authorized generic.
• Whether GYNE-SULF faces multiple competitor SKUs (strength, dosage form).
• Number and strength of blocking patents and whether they cover key product characteristics (not just broad compounds).

When does GYNE-SULF face exclusivity or patent-expiration pressure?

Featured snippet: The revenue inflection for a branded small molecule usually occurs at the first of (1) regulatory exclusivity expiry, (2) Orange Book blocking patent expiry, or (3) settlement timing that enables earlier generic availability.

Timeline framework (what investors track)

• Regulatory exclusivity (if applicable): periods tied to first approval and regulatory data protections.
• Patent estate:
  • composition-of-matter,
  • formulation,
  • method-of-use,
  • and manufacturing/process patents.
• ANDA/Paragraph IV:
  • first challenge filing date,
  • 30-month stay period,
  • settlement date and agreed entry date,
  • court rulings that narrow or eliminate barriers.

Barrier strength impact

• If patents broadly cover the formulation and are upheld, branded sales can hold longer with fewer price cuts.
• If patents are narrow or design-arounds succeed, competitor entry compresses sales quickly.

What patents protect GYNE-SULF and how strong is the patent estate?

Featured snippet: Patent strength is determined by coverage breadth (composition vs. formulation vs. method-of-use), remaining claim life, and litigation history.

Patent categories to assess for launch resistance

• Composition-of-matter: generally strongest if granted and still within life.
• Formulation: can block even when composition is old, if competitors need specific excipients/solubilizers or release characteristics.
• Method-of-use: blocks only if competitors pursue a different claim strategy and if labeling must match.

How the market responds to patent threats

• Investors price:
  • probability of generic entry within a specific calendar window,
  • likelihood of settlement,
  • and speed of post-launch price normalization.

(No patent numbers, assignees, or expiration dates were provided for GYNE-SULF, so a claim-by-claim estate map cannot be produced.)

What generic entry risks exist for GYNE-SULF?

Featured snippet: Generic risk is highest when patents are few, expiration dates are near, and competitor ANDA filings are ready to trigger early entry via settlement or court outcomes.

Entry pathways that impact timing

1. Paragraph IV ANDA challenge
   • can bring the first generic launch sooner.
2. Staggered generic launches
   • multiple ANDAs can widen competitive pressure across strengths/dosage forms.
3. Authorized generics
   • can reduce branded economics faster than standalone generic entry.

Business signals

• Multiple ANDA approvals for AB-rated products.
• Court outcomes narrowing claims.
• Settlement agreements specifying entry dates.

(No ANDA/P-IV filings, Orange Book entries, or litigation records were provided for GYNE-SULF, so launch dates cannot be quantified.)

What is the FDA and Orange Book status of GYNE-SULF?

Featured snippet: Orange Book status determines whether generic entry is blocked by listed patents for the approved drug and listed strengths.

What to verify on Orange Book

• Listed active ingredient and dosage forms.
• Drug product exclusivity vs. patent listings.
• Patent expiration per listed strength and dosage form.

(No Orange Book listings or FDA approval identifiers were provided for GYNE-SULF, so status cannot be tabulated.)

How does GYNE-SULF compare with competing drugs in its therapeutic space?

Featured snippet: Competitive share is usually won on formulary placement and net price, with clinical differentiation only mattering when payers require evidence of superiority.

Competitive comparison dimensions

• Formulary position (preferred/non-preferred)
• Net price vs. AB alternatives
• Dosing convenience (frequency, pill burden)
• Adverse event profile and tolerability
• Formulation differentiation (release, absorption, safety)

Market share outcomes

• If GYNE-SULF is the default option for a guideline subset, it may retain volume longer after generic entry via payer preference.
• If it is a second-line brand, generic displacement tends to be faster.

(No comparator list, competitor brands/generics, or indication mapping was provided.)

How do supply chain and manufacturing issues affect GYNE-SULF sales?

Featured snippet: Supply disruptions can create temporary revenue spikes but often lead to longer-term share loss if shortages allow permanent switching.

Operational factors that shift financial trajectory

• Finished goods availability and active pharmaceutical ingredient sourcing stability.
• Batch yield variability and regulatory compliance.
• Contract manufacturing capacity constraints.

What litigation, settlements, or regulatory actions affect GYNE-SULF?

Featured snippet: Litigation is a timing mechanism; settlements often convert patent uncertainty into calendar certainty for generic entry.

What to track

• Complaint filings and claim constructions.
• Injunction outcomes.
• Settlement date and agreed “carve-out” products or labeling restrictions.
• FDA decisions tied to approval of challenged ANDAs.

(No specific litigation or regulatory actions were provided for GYNE-SULF, so no docket-level chronology can be built.)

How do licensing deals influence GYNE-SULF financial performance?

Featured snippet: Licensing changes can move revenue from the brand owner to royalty streams, and can reallocate marketing spend and geographic execution risk.

Typical deal structures that change net sales

• Upfront and milestone-heavy arrangements: reduce reported volatility but cap upside.
• Territory carve-outs: concentrate performance in high-margin regions.
• Supply/royalty terms: affect gross-to-net margin more than topline.

(No licensing terms, counterparties, or geographic scopes were provided for GYNE-SULF.)

Revenue exposure analysis: what drives the upside and downside for GYNE-SULF?

Featured snippet: Upside comes from payer expansion and protected launch timing; downside comes from generic substitution, faster than expected exclusivity loss, and adverse channel shifts.

Upside levers

• New formulary listings and lower reimbursement friction.
• Expanded indications (only if supported by label changes).
• Competitive supply constraints among generic manufacturers.

Downside risks

• Early generic launch via settlement.
• Patent invalidation or design-around success.
• Increased rebate pressure and net price compression.

Key takeaways

• GYNE-SULF’s financial trajectory is governed less by clinical novelty and more by exclusivity and patent-patent-to-launch timing, then by reimbursement and net price erosion once generics enter.
• The decisive variable is the strength and remaining life of Orange Book-listed patents and any method/formulation barriers that restrict generic labeling or design-around.
• Without FDA/Orange Book identifiers, patent numbers, expiration dates, ANDA/Paragraph IV records, or litigation/sdsettlement dates for GYNE-SULF, a quantitative forecast or exact timeline cannot be constructed.

FAQs

1. What drives net sales for branded small-molecule drugs after first generic entry?
2. How do Paragraph IV ANDA challenges change the calendar for generic availability?
3. Which patent types (composition, formulation, method-of-use) most affect generic design-around strategies?
4. What Orange Book entries most strongly predict whether generics launch at risk or wait?
5. How do payer formulary tiering and prior authorization affect brand retention post-generic?

References

No sources were provided or cited because no verifiable FDA/Orange Book, patent, or litigation data for GYNE-SULF were included in the prompt.